Richard A. Messmann
Keine laufenden Positionen mehr
Profil
Richard A.
Messmann served as Director at Michigan State University and Deputy Associate Director at National Cancer Institute.
He worked as Clinical Research Physician at Eli Lilly & Co. and Vice President-Medical Affairs at Endocyte, Inc. He also served as Director-Cancer Research at Karmanos Cancer Foundation for a brief period.
Later, he became Chief Medical Officer at Sierra Oncology, Inc. Messmann holds a graduate degree from Duke University, an undergraduate degree, and a doctorate from Wayne State University (Michigan).
He also holds an undergraduate degree from Oakland University (Michigan).
Ehemalige bekannte Positionen von Richard A. Messmann
| Unternehmen | Position | Ende |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 26.05.2016 |
| ENDOCYTE, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Karmanos Cancer Foundation | Corporate Officer/Principal | 01.07.2005 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| Michigan State University | Direktor/Vorstandsmitglied | - |
Ausbildung von Richard A. Messmann
| Duke University | Graduate Degree |
| Wayne State University (Michigan) | Undergraduate Degree |
| Oakland University (Michigan) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
| Karmanos Cancer Foundation | |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |